Show simple item record

dc.contributor.authorMarasini, Nirmal
dc.contributor.authorKhalil, Zeinab G
dc.contributor.authorGiddam, Ashwini Kumar
dc.contributor.authorGhaffar, Khairunnisa Abdul
dc.contributor.authorHussein, Waleed M
dc.contributor.authorCapon, Robert J
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorGood, Michael F
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorToth, Istvan
dc.date.accessioned2018-06-15T07:36:31Z
dc.date.available2018-06-15T07:36:31Z
dc.date.issued2016
dc.identifier.issn0378-5173
dc.identifier.doi10.1016/j.ijpharm.2016.09.057
dc.identifier.urihttp://hdl.handle.net/10072/143053
dc.description.abstractRheumatic heart disease represents a leading cause of mortality caused by Group A Streptococcus (GAS) infections transmitted through the respiratory route. Although GAS infections can be treated with antibiotics these are often inadequate. An efficacious GAS vaccine holds more promise, with intranasal vaccination especially attractive, as it mimics the natural route of infections and should be able to induce mucosal IgA and systemic IgG immunity. Nanoparticles were prepared by either encapsulating or coating lipopeptide-based vaccine candidate (LCP-1) on the surface of poly(lactic-co-glycolic acid) (PLGA). In vitro study showed that encapsulation of LCP-1 vaccine into nanoparticles improved uptake and maturations of antigen-presenting cells. The immunogenicity of lipopeptide incorporated PLGA-based nanoparticles was compared with peptides co-administered with mucosal adjuvant cholera toxin B in mice upon intranasal administration. Higher levels of J14-specific salivary mucosal IgA and systemic antibody IgG titres were observed for groups immunized with encapsulated LCP-1 compared to LCP-1 coated nanoparticles or free LCP-1. Systemic antibodies obtained from LCP-1 encapsulated PLGA NPs inhibited the growth of bacteria in six different GAS strains. Our results show that PLGA-based lipopeptide delivery is a promising approach for rational design of a simple, effective and patient friendly intranasal GAS vaccine resulting in mucosal IgA response.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom410
dc.relation.ispartofpageto420
dc.relation.ispartofissue1-2
dc.relation.ispartofjournalInternational Journal of Pharmaceutics
dc.relation.ispartofvolume513
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences not elsewhere classified
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode321499
dc.titleLipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2016 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorGood, Michael F.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record